Hennessy Advisors Inc. Has $5.10 Million Position in Pfizer Inc. (NYSE:PFE)

Hennessy Advisors Inc. raised its stake in Pfizer Inc. (NYSE:PFE) by 2.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 183,800 shares of the biopharmaceutical company’s stock after purchasing an additional 5,200 shares during the period. Hennessy Advisors Inc.’s holdings in Pfizer were worth $5,100,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in PFE. Advisor OS LLC grew its holdings in shares of Pfizer by 1.0% during the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after buying an additional 365 shares during the last quarter. Safeguard Investment Advisory Group LLC increased its holdings in Pfizer by 3.9% during the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 371 shares in the last quarter. Lantz Financial LLC raised its stake in shares of Pfizer by 1.3% in the first quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $849,000 after purchasing an additional 381 shares during the last quarter. King Wealth Management Group lifted its holdings in shares of Pfizer by 2.4% in the fourth quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 388 shares in the last quarter. Finally, Advance Capital Management Inc. grew its holdings in Pfizer by 4.0% during the fourth quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock worth $293,000 after buying an additional 391 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 1.4 %

Shares of NYSE:PFE traded up $0.38 during trading on Thursday, reaching $27.80. 27,944,899 shares of the company traded hands, compared to its average volume of 40,970,031. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $37.80. The firm has a market capitalization of $157.53 billion, a price-to-earnings ratio of -458.26, a P/E/G ratio of 1.10 and a beta of 0.70. The business’s fifty day moving average is $27.81 and its 200-day moving average is $27.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.23 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 6.04%. Pfizer’s payout ratio is -2,799.53%.

Analysts Set New Price Targets

PFE has been the topic of several recent analyst reports. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Wednesday. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Finally, Morgan Stanley increased their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Ten equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.